Downstream LGR5 expression was upregulated in DAP3-deficient stomach cancer cells, while down-regulation of LGR5 re-sensitized DAP3-deficient stomach cancer cells to 5-FU and oxaliplatin. The gene discussed is LGR5; the disease is gastric neoplasm.